Page 50 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021 News provided by Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that will be presented as electronic posters during Week 1 of the American Association for Cancer Research ...

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma News provided by Share this article STOCKHOLM, March 8, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO ), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that it strengthens the leadership of the European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon as Head of Medical Affairs Europe. The Company also announced that it opens an Early Access Program a...

RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) (“Cosmo”) to manufacture two key products; RedHill's largest selling product in the U.S., Movant...

RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares USA - English Share this article Share this article TEL AVIV, Israel and RALEIGH, N.C., March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,375,000 American Depositary Shares (ADSs) of the Company, at a price to the public of $8.00 per ADS. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Co...

RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares USA - English Share this article TEL AVIV, Israel and RALEIGH, N.C., March 1, 2021  /PRNewswire/ -- RedHill Biopharma Ltd . (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,250,000 American Depositary Shares (ADSs) of the Company, at a price to the public of $8.00 per ADS, less underwriting ...